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ABSTRACT
Objectives To assess the prevalence of the main
causes of morbi-mortality in the antiphospholipid
syndrome (APS) during a 10-year-follow-up period and
to compare the frequency of early manifestations with
those that appeared later.
Methods In 1999, we started an observational study
of 1000 APS patients from 13 European countries. All
had medical histories documented when entered into the
study and were followed prospectively during the
ensuing 10 years.
Results 53.1% of the patients had primary APS, 36.2%
had APS associated with systemic lupus erythematosus and
10.7% APS associated with other diseases. Thrombotic
events appeared in 166 (16.6%) patients during the ﬁrst 5-
year period and in 115 (14.4%) during the second 5-year
period. The most common events were strokes, transient
ischaemic attacks, deep vein thromboses and pulmonary
embolism. 127 (15.5%) women became pregnant (188
pregnancies) and 72.9% of pregnancies succeeded in
having one or more live births. The most common obstetric
complication was early pregnancy loss (16.5% of the
pregnancies). Intrauterine growth restriction (26.3% of the
total live births) and prematurity (48.2%) were the most
frequent fetal morbidities. 93 (9.3%) patients died and the
most frequent causes of death were severe thrombosis
(36.5%) and infections (26.9%). Nine (0.9%) cases of
catastrophic APS occurred and 5 (55.6%) of them died.
The survival probability at 10 years was 90.7%.
Conclusions Patients with APS still develop signiﬁcant
morbidity and mortality despite current treatment. It is
imperative to increase the efforts in determining optimal
prognostic markers and therapeutic measures to prevent
these complications.
INTRODUCTION
The antiphospholipid syndrome (APS) is a systemic
autoimmune disorder where different prothrombo-
tic factors interact to induce arterial and venous
thrombosis.1 It is deﬁned by a combination of at
least one clinical feature characterised by vascular
thrombosis or pregnancy morbidity and raised
titres of antiphospholipid antibodies (aPL), namely
lupus anticoagulant (LA), anticardiolipin antibodies
(aCL) and/or anti-ß2 glycoprotein-I antibodies.2 3
In addition, there is great variety of non-
thrombotic and/or non-criteria clinical manifesta-
tions related to aPL, but the real prevalence of
most of them is unknown.3 4 Also, a rare and
severe subset of APS has been described (cata-
strophic APS) that is characterised by multiorgan
failure originated by widespread thrombotic
disease, which usually affects small vessels over a
short period of time and is associated with high
mortality rates.5 Furthermore, APS can occur either
as a primary condition (primary APS) or in associ-
ation with other autoimmune diseases, usually sys-
temic lupus erythematosus (SLE), but discordant
ﬁndings have been reported regarding the relation-
ship of APS and SLE (ie, the percentage of patients
with primary APS who develops SLE over time).6 7
During the last three decades, several studies of
patients with APS have been published, most of
them being small or short-term follow-up
cohorts.8–10 The Euro-Phospolipid project was
created in order to ﬁll some of these gaps in our
knowledge of this syndrome. This large inter-
national study, composed of 1000 European
patients with APS, has helped so far to identify the
prevalence and characteristics of the main clinical
and immunological manifestations of APS at its
onset and during a 5-year follow-up period.3 11 12
The aims of the present study were to assess the
prevalence and characteristics of the main causes of
morbidity and mortality after 10-year-follow-up
and to compare the frequency of early manifesta-
tions with those that appeared later in the evolu-
tion of the disease.
PATIENTS AND METHODS
Euro-Phospholipid project
The Euro-Phospholipid project started in 1999 as
an attempt to describe the course of APS patients
in the real life in Europe. This project was designed
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as a multicentre, consecutive and prospective observational
study. Twenty tertiary university referral centres from 13
European countries (Belgium, Bulgaria, Denmark, France,
Germany, Greece, Hungary, Israel, Italy, The Netherlands,
Portugal Spain, and the UK) participated in the study with
experienced physicians in the management of APS patients. The
observation period stopped in 2009 or at the time of the latest
patient information if lost to follow-up or at death. The study
was performed according to the principles of the Declaration of
Helsinki.
Patient selection
In order to gather a sizeable series of patients, 50 consecutive
patients from each centre were incorporated into the cohort.
The ﬁnal Euro-Phospholipid cohort included 1000 unselected
patients who met the proposed preliminary criteria for the clas-
siﬁcation of deﬁnite APS.2
The patients had been attending the referral centres between
the years 1990 and 1999, and since then all patients have been
followed up by the same physicians during the ensuing 10 years
(1999–2009) with regular visits to the outpatient clinics at least
every 3–6 months, depending on the severity of the disease and
admitted to hospital if necessary. Speciﬁcally, they attended
departments of rheumatology (seven centres), clinical immun-
ology/autoimmune diseases (six centres), internal medicine (ﬁve
centres) and haematology/haemostasis (two centres).
All patients had their medical histories documented and
underwent a medical interview as well as a routine general phys-
ical examination by a qualiﬁed internist and/or rheumatologist.
A protocol form was used to record the clinical and serological
characteristics of the patients.3 The underlying autoimmune
disease was considered when the patient met the speciﬁc criteria
as previously established.13–18
Deﬁnition of clinical features
To minimise possible interobserver bias and to monitor the accur-
acy of the data collection, a standard protocol was used and the
inclusion criteria and variables of this protocol were carefully dis-
cussed by all the participating physicians on several occasions.
These variables included causes of morbidity (APS manifestations
and other associated medical problems), causes of death and sur-
vival. The main APS clinical manifestations evaluated in this pro-
spective study have been described previously.3 19 20 Patients were
considered to have catastrophic APS if they presented with an
acutely devastating APS with multiple organ (>3) involvement,
mainly affecting small vessels supplying organs and presenting
over a short period of time (<1 week).21
Pregnancy morbidity was considered when the following
established deﬁnitions were fulﬁlled: (a) one or more unex-
plained deaths of a morphologically normal fetus at or beyond
the 10th week of gestation, with normal fetal morphology docu-
mented by ultrasound or by direct examination of the fetus;
or (b) one or more premature births of a morphologically
normal neonate before the 34th week of gestation because of
eclampsia or severe pre-eclampsia deﬁned according to standard
deﬁnitions, or recognised features of placental insufﬁciency; or
(c) three or more unexplained consecutive spontaneous abor-
tions before the 10th week of gestation, with maternal anatom-
ical or hormonal abnormalities and paternal and maternal
chromosomal causes excluded.2
The main clinical manifestations related to SLE evaluated in
this study were deﬁned according to the American Rheumatism
Association glossary committee and are described in detail else-
where.22 Diagnoses of vascular risk factors and other associated
medical problems that appeared during the study (infections,
malignancies, haemorrhages, drug side effects, etc.) were per-
formed on clinical grounds and conﬁrmed by appropriate com-
plementary techniques.11 12 The causes of death were based on
information obtained from the clinicians in charge, autopsy
reports and/or death certiﬁcates.
Laboratory studies
The presence of aCL of IgG and IgM isotypes was measured by
a β2-glycoprotein I-dependent ELISA.23 They were considered
positive if present in medium to high titre (>40 GPL or >40
MPL) on two or more occasions, at least 6 weeks apart.
LA activity was detected by coagulation assays according to the
guidelines of the International Society on Thrombosis and
Haemostasis (Scientiﬁc Subcommittee on Lupus Anticoagulants/
Phospholipid-Dependent Antibodies).24 Antinuclear antibodies
(ANA) were determined by indirect immunoﬂuorescence on
mouse liver and HEp-2 cell substrate. Anti-double-stranded
DNA (anti-dsDNA) antibodies were determined by Farr’s
ammonium sulfate precipitation technique, ELISA and indirect
immunoﬂuorescence on Crithidia luciliae substrate. Precipitating
antibodies to extractable nuclear antigens, including Ro/SSA,
La/SSB, U1 small nuclear RNP and Sm, were detected by ELISA
and counter immunoelectrophoresis using calf and rabbit
thymus and human spleen extracts. Rheumatoid factor was
detected by latex and Rose–Waaler tests. All these tests were per-
formed in referral laboratories that adhere to strict quality con-
trols and are participating in the standardisation project of the
European Forum on aPL.
Statistical analysis
The following independent variables were included in the statis-
tical analysis for the detection of possible predictors of the out-
comes of interest (ie, thrombotic events, pregnancy morbidity
and mortality): primary APS, SLE, gender, age at onset of APS,
comorbidities (diabetes mellitus, hypertension, dyslipidemia and
smoking) and aPL (IgG aCL, IgM aCL and LA). Univariate and
multivariate Cox proportional hazard regression tests were used
to determine associations of our outcomes of interest (depend-
ent variables) with the different independent variables. When
several independent variables appeared to have statistical signiﬁ-
cance in the univariate analysis, they were included in the multi-
variate analysis. Results of the analysis of continuous variables
are indicated as mean SD. Survival time was deﬁned as the inter-
val from the time the patient entered in the study until death or
last contact. Survival probabilities were calculated according
to Kaplan–Meier lifetime analysis method. The Standardized
Mortality Ratio (SMR) was used to compare the mortality risk
of patients with APS to that of the general population of the
European Union. SMR and its asymptotic 95% CI were calcu-
lated as follows:
SMR ¼O=E
95%CI ¼ðSMR 1:96pO=E; SMRþ 1:96pO=EÞ
where O is the observed number of deaths in the study popula-
tion and E is the expected number of deaths.25 Statistical signiﬁ-
cance was deﬁned as a p Value <0.05. Statistical analyses were
performed by means of the SPSS program (SPSS, Chicago,
Illinois, USA) using the information stored in the database
program.
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RESULTS
Patient characteristics at the beginning of the prospective
study
The entire cohort consisted of 820 (82.0%) female and 180
(18.0%) male patients. There were 985 (98.5%) Caucasians,
5 (0.5%) blacks and 10 (1.0%) patients of other races. Mean
(SD) age at study entry was 42 (14) years (range 0–82; median
40). The most prevalent thrombotic risk factors were smoking,
hypertension and dyslipidemia, present in 15–20% of the total
cohort. In total, 53.1% of the patients had primary APS, 36.2%
had APS associated with SLE, 5.0% APS associated with lupus-
like syndrome and 5.7% APS associated with other diseases.
During the study, eight patients diagnosed at entry as primary
APS developed anti-dsDNA antibodies and were reclassiﬁed as
lupus-like syndrome; also during the last 5 years of the study,
three patients were reclassiﬁed as SLE-associated APS. During
the 10 years of the study, 419 (41.9%) patients were lost to
follow-up, excluding deaths (mean 4% every year): 151 patients
during the ﬁrst 5 years and 215 during the ensuing 5 years.
The main clinical manifestations at the onset of the disease,
the cumulative clinical manifestations from the onset of the
disease until the beginning of the study and the immunological
ﬁndings when the patients entered into the study and during the
initial 5 years of follow-up have been reported in detail
elsewhere.3 11
APS manifestations during the study period
The frequencies of the main APS clinical manifestations accumu-
lated from the onset of the disease to the inclusion in the study
and during the 10-year follow-up are shown in table 1. We com-
pared the manifestations that appeared during the initial 5 years
of the observational period (1999–2004) with those that
appeared in the ensuing 5 years (2004–2009).
During the 10-year period, the most frequent manifestation
was thrombosis. Thrombotic events appeared in 166 (16.6%)
patients during the ﬁrst 5-year period of the study and in
118 patients (15.3%) during the second period. The most
common thrombotic events were strokes (5.3% of the total
cohort), transient ischaemic attacks (4.7%), deep vein throm-
boses (4.3%) and pulmonary embolism (3.5%). Similar propor-
tions appeared in the ﬁrst and the second periods.
Additionally, other APS-related manifestations not included
in the classiﬁcation criteria for APS (non-criteria APS manifes-
tations) were also commonly observed during the study, includ-
ing thrombocytopenia (8.7%), livedo reticularis (8.1%),
autoimmune haemolytic anaemia (4%), valve thickening/dys-
function (4.6%), epilepsy (3.2%) and skin ulcers (3.1%)
(table 1).
During the 10-year follow-up period, 127 (15.5%) women
became pregnant (range 1–4). A total of 188 pregnancies
occurred and 72.9% of pregnancies succeeded in having one or
more live births (range 1–3; total number of live births 137).
The most common obstetric complication was early pregnancy
loss (<10 weeks) that appeared in 16.5% of pregnancies. The
obstetric morbidity rate was lower during the last 5 years of the
study so that no women developed pre-eclampsia/eclampsia.
Regarding fetal morbidity, the most frequent manifestations
were birth prematurity (48.2% of the total live birth) and intra-
uterine growth restriction (26.3%).
A total of nine patients developed an episode of catastrophic
APS during the ﬁrst 5-year follow-up period but none during
the second period.
Table 1 Main clinical manifestations related to the APS that appeared during the 10-year follow-up (1999–2009) of the total cohort of 1000
patients
Clinical manifestation*
0 year† (n=1000)
No. (%)
0–5 year (n=1000)
No. (%)
5–10 year (n=796)‡
No (%)
0–10 year (n=1000)
No (%)
Thrombocytopenia (<100 000/mL) 296 (29.6) 37 (3.7) 50 (6.3) 87 (8.7)
Livedo reticularis 241 (24.1) 26 (2.6) 55 (6.9) 81 (8.1)
Stroke 198 (19.8) 24 (2.4) 29 (3.6) 53 (5.3)
Transient ischaemic attacks 111 (11.1) 23 (2.3) 24 (3.0) 47 (4.7)
Deep vein thrombosis 389 (38.9) 21 (2.1) 22 (2.7) 43 (4.3)
Pulmonary embolism 141 (14.1) 21 (2.1) 14 (1.7) 35 (3.5)
Epilepsy 70 (7.0) 17 (1.7) 15 (1.9) 32 (3.2)
Skin ulcers 55 (5.5) 17 (1.7) 14 (1.7) 31 (3.1)
Valve thickening/dysfunction 116 (11.6) 17 (1.7) 29 (3.6) 46 (4.6)
Vegetations 27 (2.7) 14 (1.4) 7 (0.9) 21 (2.1)
Myocardial infarction 55 (5.5) 9 (0.9) 10 (1.2) 19 (1.9)
Superficial thrombophlebitis 117 (11.7) 9 (0.9) 8 (1.0) 17 (1.7)
Autoimmune haemolytic anaemia 97 (9.7) 9 (0.9) 31 (3.9) 40 (4.0)
Obstetric manifestation§ (n=1580) (n=105) (n=83) (n=188)
Pre-eclampsia/eclampsia 82 (5.2) 8 (7.6) 4 (4.8) 12 (6.4)
Early pregnancy loss (<10 weeks) 560 (35.4) 18 (17.1) 13 (15.7) 31 (16.5)
Late pregnancy loss (≥10 weeks) 267 (16.9) 7 (6.7) 2 (2.4) 9 (4.8)
Live birth 753 (47.6) 80 (76.2) 57 (68.7) 137 (72.9)
Live birth with prematurity¶ 80 (10.6) 28 (35.0) 38 (66.7) 66 (48.2)
Live birth with intrauterine growth restriction¶ 11 (1.5) 11 (13.7) 25 (43.8) 36 (26.3)
*Some patients had several associated presenting manifestations.
†Cumulative clinical manifestations at baseline. Previous period: median 6 years.
‡Number of patients that continued in the study in 2004.
§Obstetric manifestation related to number of pregnancy (n). Some women had more than one pregnancy.
¶Percentage related to number of live births.
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In the multivariate analysis, no statistical differences were
detected in the occurrence of APS manifestations depending on
the gender, the age at onset of APS or the presence of
comorbidities. The most common underlying autoimmune
disease was SLE. Of those 132 (22.7%) patients with APS asso-
ciated with SLE, 84% were females and 16% males. The mean
age (SD) at inclusion was 46 (10) years, and this was lower in
comparison with those with primary APS (50 (12) years,
p<0.002). Regarding clinical manifestations (SLE vs primary
APS), we observed that both groups had similar thrombotic and
obstetric proﬁles, with some exceptions that have signiﬁcant
statistical differences. Patients with APS associated with SLE
developed more frequently arthralgias (31.1% vs 8.1%) and
arthritis (21.2% vs 2.8%), leucopenia (14.4% vs 2.4%), auto-
immune haemolytic anaemia (15.9% vs 2.1%), livedo reticularis
(21.2% vs 6.9%), epilepsy (6.8% vs 1.2%), glomerular throm-
bosis (3.0% vs 0.2%) and myocardial infarction (3.8% vs 1.2%)
compared with primary APS patients who developed more fre-
quently superﬁcial thrombophlebitis (0% vs 1.9%) and fetal
morbidity such as birth prematurity (40% vs 72.3%) and intra-
uterine growth restriction (1% vs 51.1%). Tables 2 and 3 depict
the main thrombotic and obstetric manifestations related to APS
associated with SLE and primary APS patients.
Laboratory features during the study period
The most prevalent immunological features during the 10-year
follow-up period were aCL (81.7%), LA (36.3%), ANA (36.3%)
and anti-dsDNA antibodies (12.7%). No signiﬁcant statistical
differences were found in the clinical presentation of the APS
according to the presence or absence of any of these antibodies.
Furthermore, LA, ANA, anti-dsDNA, anti-Ro/SSA, anti-La/SSB,
anti-RNP and anti-Sm antibodies were more frequent in patients
with APS associated with SLE compared with primary APS
(p<0.001).
APS treatment during the study period
During the 10-year study, the majority of patients received
antithrombotic treatment. Low doses of antiaggregant agents
were used in 35.0% of the patients during the initial 5-year
period and in 27.7% of the patients during the ensuing 5 years
(86% aspirin and 12% other antiplatelet). In this last period,
double antiplatelet therapy was administered in 1.8% of
patients. On the other hand, 40.2% of the patients received oral
anticoagulants during the ﬁrst period and 37.0% of patients
during the second follow-up period (62% of them at a target
international normalised ratio (INR) of 2–3 and 38% at a target
INR 3–4). Also during this last 5 years, 12.4% of patients were
taking the association of antiplatelet and anticoagulant treat-
ment and 21.1% of patients did not receive any kind of antith-
rombotic treatment.
During the last 5-year follow-up period, 24.8% of patients on
antithrombotic treatment (20% antiplatelet, 45% anticoagulant,
35% both treatments associated) and 5.2% of patients without
any antithrombotic treatment developed thrombosis. In add-
ition, 8.3% of patients under antithrombotic therapy (62.2%
antiaggregant, 29.7% anticoagulant, 8.1% both treatments asso-
ciated) and 1.5% of patients without any antithrombotic treat-
ment developed APS-related obstetric complications.
Of those 135 patients who did not receive any antithrombotic
treatment throughout this follow-up period, 93.3% and 97.0%
were free of thrombotic complication and obstetric events,
respectively.
No signiﬁcant statistical differences were found in the antith-
rombotic treatment related to the underlying autoimmune
disease (APS associated with SLE/primary APS).
During the 10-year study, 61 major bleeding episodes were
developed in patients on antithrombotic treatments, 33% of
them at a target INR>3 (50.8% musculocutaneous, 24.6% cere-
bral, 16.4% gastrointestinal and 8.2% intra-abdominal) of
which 10 (16.4%) were fatal.
Mortality and causes of death during the study period
During the 10-year period, 93 (9.3%) patients (72 female and
21 male) died. The mortality rate was similar in both periods:
5.3% in the initial 5-year follow-up period and 4% in the
ensuing 5 years. Mean (SD) age at death was 59 (14) years
(range 19–94). The unadjusted SMR for the total cohort was
1.8 (95% CI 1.5 to 2.1) in comparison with the general popula-
tion of the area studied. There was no difference in the mortal-
ity rate regarding underlying disease: 6.8% of patients with APS
Table 2 Main thrombotic manifestations related to APS
associated with SLE and primary APS that appeared during the
10-year follow-up (1999–2009) of the ‘Euro-Phospholipid’ cohort
Thrombotic
manifestations*
APS associated with
SLE (n=132)†
No. (%)
Primary APS
(n=420)†
No. (%)
p
Value‡
Superficial
thrombophlebitis
0 8 (1.9) 0.036
Deep vein thrombosis 4 (3.0) 18 (4.3)
Stroke 9 (6.8) 20 (4.8)
Transient ischaemic
attacks
8 (3.1) 13 (3.1)
Myocardial infarction 5 (3.8) 5 (1.2) 0.050
Unstable angina 4 (3.0) 10 (2.4)
Pulmonary embolism 4 (3.0) 9 (2.1)
Glomerular thrombosis 4 (3.0) 1 (0.2) 0.003
*Some patients had several associated presenting manifestations.
†Number of patients that continued in the study until 2009 (230 patients with APS
associated with SLE were lost).
‡Pearson χ2.
APS, antiphospholipid syndrome; SLE, systemic lupus erythematosus.
Table 3 Main obstetric manifestations related to APS associated
with SLE and primary APS that appeared during the 10-year
follow-up (1999–2009) of the ‘Euro-Phospholipid’ cohort
Obstetric manifestations
APS associated
with SLE (n=14)*
No. (%)
Primary APS
(n=65)*
No. (%) p Value†
Pre-eclampsia/eclampsia‡ 1 (7.1) 3 (4.6)
Early pregnancy loss
(<10 weeks)‡
3 (21.4) 10 (15.3)
Late pregnancy loss
(≥10 weeks)‡
0 2 (2.4)
Live birth‡ 10 (71.4) 47 (72.3)
Live birth with
prematurity§
4 (40.0) 34 (72.3) 0.045
Live birth with
intrauterine growth
restriction§
1 (0.1) 24 (51.1) 0.017
*Number of pregnancies. Some women had more than one pregnancy.
‡Obstetric manifestation related to number of pregnancies.
†Pearson χ2.
§Fetal complications, percentage related to number of live births.
APS, antiphospholipid syndrome; SLE, systemic lupus erythematosus.
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associated with SLE and 7.1% of patients with primary APS
died.
During the observational period, after performing the multi-
variate analysis, no statistical differences were detected in the
causes of death depending on the underlying disease (primary
APS or SLE) or on the treatment that patients were receiving
(immunosuppressive or anticoagulant agents).
The most common causes of death were severe thrombotic
events, including myocardial infarction, strokes and pulmonary
embolism (36.5% of total deaths), infections (26.9%: bacterial
21.5%, other 5.4%) and haemorrhages (10.7%). Five out of the
nine (55.6%) patients who developed catastrophic APS died.
Table 4 shows the main causes of death of the total cohort and
table 5 related to primary APS and APS associated with SLE.
A survival probability of 94% was found at 5 years from the
time of entry into the study and of 91% at 10-year follow-up
(ﬁgure 1). There were no differences in survival probabilities
between patients with primary APS and those associated with SLE.
DISCUSSION
The Euro-Phospholipid project is a prospective observational
study of a cohort of 1000 European patients that fulﬁlled classi-
ﬁcation criteria of deﬁnite APS.2 In this paper, we have
described the prevalence and characteristic of the main clinical
manifestations as well as the mortality rate and causes of death
in this cohort during a 10-year period (1999–2009). In add-
ition, we compared these results with the accumulated data
from the onset of the disease to the inclusion in this study.3
The strength of this study, as compared with other European
series,10 26 27 lies in its multicentre design, including centres
from countries across all Europe, thus covering a very represen-
tative sample of the European APS population. The limitation
regarding the possible differences between the participating hos-
pitals has been overcome by a strict selection of tertiary referral
university centres with physicians experienced in the manage-
ment of APS and by establishing a well-deﬁned protocol.
A potential selection bias by solely choosing tertiary referral
centres is improbable because the majority of patients with APS
from these countries were referred to these centres.
Probably, the major study limitation has been the losses
during the 10-year period of follow-up (41.9% of patients,
excluding deaths), but this accounted for only 4% of the total
cohort every year and appearance or absence of the different
outcome variables during the period of time that these patients
participated in the study was also registered. Therefore, this
cohort can be considered representative of what are currently
accepted to be APS patients in Europe.
In this European cohort, the most common clinical manifesta-
tions were thrombotic events, with a similar incidence among
the ﬁrst 5 years of follow-up period compared with the ensuing
5 years. However, the frequencies are lower compared with the
cumulative clinical manifestations before the start of the study
(median previous period of evolution, 6 years)3 and compared
with other studies in other European,10 American28 and Asian
series.29 These lower frequencies could be due to genetic or
Table 5 Main causes of death related to antiphospholipid
syndrome (APS) associated with systemic lupus erythematosus (SLE)
and primary APS that appeared during the 10-year follow-up
(1999–2009) of the ‘Euro-Phospholipid’ cohort
Causes of death*
APS associated to SLE
(n=9)†
No. (%)
Primary APS
(n=30)†
No. (%)
Myocardial infarction 0 3 (10)
Stroke 1 (11.1) 3 (10)
SLE renal involvement 1 (11.1) 0
SLE haematological
involvement
1 (11.1) 0
Bacterial infection 3 (33.3) 6 (20)
Viral infection 0 3 (10)
Malignancy 1 (11.1) 6 (20)
Haemorrhage 2 (22.2) 7 (23)
*Several patients had more than one cause of death.
†Percentage of death.
Figure 1 Kaplan–Meier survival curve of the total cohort showing a
94.7% probability of remaining alive at 5 years and 90.7% at 10 years
from the time of entry into the study.
Table 4 Causes of death during the 10 year follow-up (1999–
2009) of the total cohort of 1000 patients
Causes of death*
0–5 year
(n=53)
No. (%)†
5–10 year
(n=40)
No. (%)†
0–10 year
(n=93)
No. (%)†
Bacterial infection 11 (20.8) 9 (22.5) 20 (21.5)
Myocardial infarction 10 (18.9) 3 (7.5) 13 (13.9)
Stroke 7 (13.2) 4 (10) 11 (11.8)
Haemorrhage 6 (11.3) 4 (10) 10 (10.7)
Malignancy 6 (11.3) 7 (17.4) 13 (13.9)
Catastrophic APS 5 (9.4) 0 5 (5.4)
Pulmonary embolism 5 (9.4) 0 5 (5.4)
SLE pulmonary involvement 3 (5.7) 0 3 (3.2)
SLE renal involvement 2 (3.8) 1 (2.5) 2 (2.5)
SLE central nervous system
involvement
1 (1.9) 0 1 (1.1)
SLE haematological
involvement
0 1 (2.5) 1 (1.1)
Chronic renal failure 0 2 (5) 2 (2.5)
Viral infection 0 4 (10) 4 (4.3)
Fungal infection 1 (1.9) 0 1 (1.1)
Trauma/accident 0 3 (7.5) 3 (3.2)
Unknown 0 3 (7.5) 3 (3.2)
*Several patients had more than one cause of death.
†Percentage of death.
APS, antiphospholipid syndrome; SLE, systemic lupus erythematosus.
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environmental differences, but could also reﬂect the effect of
medical care during the study because of the prospective nature
of the Euro-Phospholipid project. Interestingly, the most
common thrombotic events at baseline were deep vein throm-
boses, but during the study we observed a higher incidence of
arterial thrombotic events (stroke, transient ischaemic attacks
and acute myocardial infarction), as it has been also found in
other studies.28 30
Additionally, several APS-related manifestations not included
in the classiﬁcation criteria were also common, including haem-
atological manifestations (thrombocytopenia and haemolytic
anaemia), livedo reticularis, epilepsy, skin ulcers and valve thick-
ening/dysfunction.
One of the characteristic clinical manifestations of the APS is
fetal morbidity, including early and late pregnancy losses, intra-
uterine growth restriction and prematurity. Additionally, mater-
nal morbidity (pre-eclampsia, eclampsia and abruptio placentae)
is also relatively common in pregnant patients with APS. The
most common fetal complications in our cohort were premature
birth and intrauterine growth restriction, while the most
common obstetric maternal complication was pre-eclampsia.
During the study, only a small percentage of patients from this
cohort became pregnant (15.5%) compared with a higher pro-
portion of patients with history of pregnancy at the study entry
(71.9%).3 However, 72.9% succeeded in having one or more
live births being signiﬁcantly higher than the 47.6% at baseline.
Probably because of this increase in successful pregnancies, the
percentage of fetal morbidity (intrauterine growth restriction
and prematurity births) was higher.3 Also, pregnancy loss and
obstetric morbidity (pre-eclampsia/eclampsia) rates were lower
during the study and were reduced to more than half in the last
5 years of follow-up. These lower frequencies probably reﬂect
the effect of therapy and medical care during the study, but also
represent the improvement in the management of the obstetric
APS patients during the last decade with the widespread use of
antiaggregant and anticoagulant drugs and the careful monitor-
ing of pregnancies.31–33
The catastrophic APS was described in 1992 by Asherson34 as
a APS subset characterised by multiple vascular occlusive events,
usually affecting small vessels supplying organs and presenting
over a short period of time (less than a week). It is considered
to be one of the most severe complications of the APS, and
about half of the patients succumb despite seemingly adequate
treatment, including anticoagulation, steroids, plasma exchange
and intravenous immunoglobulins.35 In this study, the incidence
of this catastrophic subset in the 10-year period was found to be
around 0.9% and the mortality rate was 55.6% (5/9 patients),
similar to other patient series in the same decade.36
The frequencies of the major immunological APS features in
our cohort were also comparable to those of other reports.3 6 37
Neither individual aPL nor the combination of some of them
was associated with an increased incidence of any speciﬁc clin-
ical manifestation. This lack of association during the study
period is probably due to the relatively low prevalence of new
APS clinical manifestations. In addition to aPL, ANA were
detected at some time during the course of the illness, but
usually at low titres, and high titres of anti-dsDNA antibodies
were found in patients with associated SLE. As in the baseline
study, we observed that patients with APS associated with SLE
had more episodes of arthritis, leucopenia, anaemia, livedo
reticularis, epilepsy and glomerular thrombosis compared with
primary APS.3
The vast majority of patients in this cohort were under antith-
rombotic treatment during the 10-year follow-up period. While
treatment has led to a reduction in the frequency of venous
thrombotic events compared with baseline data, it does not
seem to produce an important impact on the frequency of arter-
ial events. This may be related to the fact that this particular
group of patients may need a higher anticoagulation target
(INR 3–4) as well as strict control of comorbidities and pro-
thrombotic factors. Moreover, some authors had suggested that
the concomitant use of immunosuppressive drugs such as those
that produce B cell modulation/depletion or the use of antima-
larials might help prevent the recurrence of new arterial
events.38
On the other hand, 23% of patients in this cohort were not
receiving antithrombotic treatment during this study period.
This may reﬂect the ‘real world’ situation of this disease. Many
physicians may have discontinued anticoagulant treatment after
long-term follow-up without recurrent events, while others may
still be unenthusiastic to prescribe primary thromboprophylaxis
to those female patients with APS who had experienced preg-
nancy morbidity or long-term secondary thromboprophylaxis
several years after the APS thrombotic event.
Despite the overall reduction of thrombotic events during the
10 years of follow-up as compared with baseline data, low-dose
aspirin did not prevent thrombotic events in 79 patients,
90 patients on anticoagulants presented new recurrent throm-
botic events during the initial 5-year period (21 of them at a
target INR >3) and 87 patients during the ensuing 5-year
period (37 of them at a target INR >3). This may reﬂect a selec-
tion bias (patients with more severe clinical manifestations may
be more consistently treated with oral anticoagulants by their
doctors), but we believe that this was probably because many
patients with APS could not keep their target INR. Therefore,
the INR at the time of the event would have much more value
than the target INR, but these data were not consistently
obtained in the study. Also, this difﬁculty to obtain a stable INR
may be a reason to develop some adverse effects of treatment
such as bleeding. Sixty-one haemorrhages occurred during the
10-year follow-up period; 30 of them in internal organs and 10
of them were the main cause of death. These problems of
current oral vitamin K antagonists having numerous drug and
dietary interactions that lead to an obliged regular, inconvenient
and costly monitoring of the INR may be overpassed by the use
of novel anticoagulants (competitive and reversible direct factor
IIa and Xa inhibitors). However, adequately powered prospect-
ive randomised controlled multicentre clinical trials are needed
to compare the efﬁcacy of the new oral anticoagulants versus
oral vitamin K antagonists in patients with thrombotic APS.
The total mortality rate during the observational period was
9.3%, higher than the mortality rate in a European SLE cohort
of 1000 patients (‘Euro-lupus cohort’) (6.8%) during a similar
period.39 The predominant causes of death were severe throm-
boses (stroke, myocardial infarction, pulmonary embolism or
catastrophic APS) and accounted for more than one-third of
deaths. In the ‘Euro-lupus cohort’, all patients who died because
of thrombosis had SLE associated with APS, and the most
common fatal thrombosis were the same and with similar inci-
dences rates to that in the Euro-Phospholipid project.39
When we compared the initial 5 years of follow-up with the
ensuing 5 years, mortality rates were similar in both follow-up
periods. However, some differences were detected: the fatal
thrombotic events were higher during the initial period and the
incidence of death because of malignancy becoming more fre-
quent during the last period. Also, infections and bleedings
accounted for one-third of deaths during the long-term study,
appearing in similar percentages during both periods.
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We were not able to identify any clinical or immunological par-
ameter with prognostic signiﬁcance for mortality. Interestingly,
although survival probability decreased during the 10-year
period, in our study older age was not associated with increased
mortality. This may be due to the fact the APS-related conditions
dominated the causes of mortality in this cohort, but also because
the population was not very old.
In conclusion, this long-term study provides updated informa-
tion on APS morbidity and mortality characteristics. Patients
with APS still develop signiﬁcant morbidity and mortality
despite current treatment (mainly oral anticoagulants and/or
antiaggregant agents); therefore, it is imperative to increase the
effort in determining optimal prognostic markers and thera-
peutic measures to prevent these important complications of the
APS.
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